Quoin Outlicenses Lead Asset For Skin Disorder In Middle East, North Africa

Quoin Pharmaceuticals Ltd QNRX has entered into an exclusive License and Distribution Agreement with Genpharm Services for QRX003 for Netherton Syndrome.
Under the agreement terms, Genpharm has exclusive rights to commercialize QRX003 in the Middle East and North Africa region upon receiving regulatory approvals in both territories.
The companies have also entered into an exclusive Supply Agreement, under which Quoin will manufacture and supply the product to Genpharm Services.
Deal terms were not disclosed.
Netherton Syndrome is a rare, hereditary skin disorder.
Related Link: Quoin, AFT Pharmaceuticals Ink Licensing Pact For Lead Candidate In Genetic Skin Disease.
Price Action: QNRX shares are down 18.6% at $5.62 during the market session on the last check Thursday.